ASPEN AEROGELS INC

source: coverage-next-full ticker: ASPN step: 01 title: Business Model Overview date: 2026-06-17

Step 01 — Business Model Overview: Aspen Aerogels (ASPN)

1. Executive Summary

Aspen Aerogels is a specialty materials manufacturer with a 20-year track record in aerogel insulation and a more recent — and far more volatile — bet on EV battery safety. The company commercializes aerogel technology across two structurally distinct businesses: a mature, cash-generative Energy Industrial (EI) segment selling high-performance insulation to oil & gas, LNG, and industrial customers; and a high-growth, customer-concentrated Thermal Barrier (TB) segment supplying PyroThin thermal runaway barriers almost exclusively to General Motors for its Ultium EV platform. [S2]

The bifurcation of these two segments creates an unusual analytical challenge. EI is a durable niche franchise with 20+ years of customer relationships, diversified end markets, and relatively predictable demand. TB, by contrast, is a single-customer, single-platform business that scaled from near-zero to $307M in FY2024 revenue before collapsing to $169M in FY2025 and continuing to fall sharply in Q1 2026 ($37.9M total company revenue). [S2][S3] The investment case for ASPN at a $482M market cap is almost entirely a bet on whether GM's Ultium EV program recovers, whether ASPN can qualify additional OEM customers, and whether the Statesboro manufacturing write-off signals permanent overcapacity or a rational reset. [S2]

2. Business Model Description

Products

ASPN's product portfolio derives from a single materials science platform — silica aerogel — engineered into distinct form factors for different thermal management applications:

• Pyrogel XT / XT-E: High-temperature aerogel blankets (rated to 650°C+) for industrial pipe insulation, process equipment, and power generation. The EI workhorse. [S3]
• Cryogel Z: Cryogenic aerogel blankets for LNG infrastructure, cold storage, and subsea pipelines requiring sub-ambient insulation with moisture resistance. [S3]
• PyroThin: Thin aerogel pads/sheets (~1–3mm) inserted between EV battery cells or modules. The pad does not prevent a cell from failing but prevents thermal runaway from propagating to adjacent cells — a critical automotive safety requirement. [S3][S8]

All three are sold as engineered materials, not complete systems. ASPN does not design or manufacture battery packs or insulation systems; it supplies a critical material component that must be engineered into the customer's design.

Customers and Channels

Energy Industrial: Revenue flows through industrial distribution (insulators, contractors, distributors) to end users in oil & gas (upstream/midstream/downstream), LNG terminals, petrochemical plants, and building & construction. No single EI customer approaches 10% of total revenue, giving the segment genuine diversification. [S2] LNG infrastructure buildout — U.S. LNG export capacity expansion — is the primary growth lever within EI.

Thermal Barrier: Almost exclusively General Motors under the Ultium platform supply agreement. Customer concentration in FY2024 was reported at approximately 95%+ of TB segment revenue. [S2][S3] ASPN has disclosed pursuing OEM qualifications with additional EV customers, but none have contributed meaningful revenue through Q1 2026.

Revenue Model

Product sales, not subscriptions or licensing. ASPN recognizes revenue on product shipment/delivery. TB operates under a long-term supply agreement with GM that includes volume commitments and pricing schedules, but GM retains the right to adjust production schedules — which is precisely what happened in FY2025 as GM decelerated Ultium platform rollout. [S2] EI is a mix of project-based sales and blanket purchase orders; it does not carry the same contractual revenue visibility as TB in theory, though in practice EI has proven far more stable. [S2]

There are no meaningful recurring revenue streams (no maintenance contracts, no SaaS-equivalent, no licensing). This is a product manufacturing business with all attendant working capital dynamics — receivables, inventory, and capex intensity.

3. Value Chain Layer Map

Raw Materials                Processing              Distribution           End Use
─────────────────────────────────────────────────────────────────────────────────
Silica precursors        →   ASPN Manufacturing  →  [EI] Distributors  →  Oil & Gas / LNG
Reinforcing fibers           East Providence, RI     Insulators             Industrial Plants
Chemical additives           (sole active plant)                            LNG Terminals
                                                 →  [TB] Direct OEM   →  GM Ultium EV Platform
                                                     (GM, prospective       Battery Packs
                                                      new OEMs)

ASPN occupies the processing/manufacturing layer. Its upstream dependencies — silica precursors, reinforcing fibers, specialty chemicals — are commodity or near-commodity inputs, though supply reliability matters in a capital-intensive continuous process. Downstream, the EI channel adds a layer of distribution margin absorption; ASPN does not control end-customer relationships in EI. For TB, ASPN has direct OEM relationships but faces the demand risk of being entirely downstream of GM's production decisions. [S2]

The most significant value-chain risk: ASPN has no ability to pull demand forward. If GM cuts Ultium production volumes, ASPN has a single plant, a fixed cost base, and no alternative customer of scale to absorb idle capacity.

4. Segment Analysis

Energy Industrial (EI)

Revenue: ~$99M (FY2021) → ~$146M (FY2024) → ~$102M (FY2025). The FY2025 decline is notable — the segment is not immune to industrial capex cycles, and FY2025 saw softness in oil & gas project starts. [S2]

Economics: EI carries positive gross margins and contributes to ASPN's fixed cost coverage. Before the TB ramp, EI was the only revenue source and sustained the business through thin years. Gross margins in EI are meaningfully lower than TB at peak, but more stable. [S3]

End markets: U.S. LNG export infrastructure is structurally positive for Cryogel demand over the next decade. The pace of FERC approvals and LNG project FIDs is the external variable ASPN cannot control. Pyrogel demand tracks industrial MRO and capex spending, which is cyclical. [S9]

Customer profile: Fragmented, diversified, no single customer dominant. EI is the business ASPN would be if TB had never existed — a profitable specialty materials niche with moderate growth and low customer concentration risk.

Growth profile: Mid-single-digit organic growth in a normal industrial environment, with upside if U.S. LNG export capacity additions accelerate Cryogel adoption. Not a hypergrowth segment. [S9]

Thermal Barrier (TB)

Revenue: ~$5M (FY2021) → ~$307M (FY2024) → ~$169M (FY2025), with Q1 2026 suggesting continued significant decline on a run-rate basis. [S2][S3]

Economics: TB commanded premium pricing during the ramp — PyroThin is a patented, OEM-qualified product with no Western-made aerogel competitor at scale. Gross margins at peak were substantially above EI. But the segment's cost structure is partially fixed (manufacturing overhead, depreciation on the Statesboro facility before write-off), so the volume collapse has a non-linear impact on profitability. [S2]

Customer profile: General Motors — specifically the Ultium battery platform — accounts for essentially all TB revenue. GM decelerated Ultium production in FY2025 and into 2026 as it recalibrated its EV rollout timeline against weaker-than-anticipated consumer EV demand in the U.S. [S8]

Qualification moat: This is TB's key structural advantage. An OEM EV thermal barrier qualification typically takes 3–5 years of engineering validation, abuse testing, and crash/fire certification. PyroThin has completed this process with GM; competing materials or new entrants would need to replicate the same 3–5 year runway before displacing ASPN at GM. ASPN is also pursuing qualification with additional OEMs, but qualification pipelines are not public. [S3][S8]

Growth profile: Binary. If GM's Ultium volumes recover and/or new OEM qualifications convert, TB is a $300M+ revenue segment with substantial operating leverage. If GM's EV strategy stalls or GM diversifies to competing thermal management solutions, ASPN faces existential revenue risk given the cost structure built for $300M+ throughput. [S2][S9]

5. Technology Foundation

Why aerogel? Aerogel is a silica-based solid comprising 95%+ air by volume, producing thermal conductivity values 2–5x lower than conventional insulation materials (mineral wool, PIR foam, fiberglass). In industrial applications where space constraints limit insulation thickness, no other material achieves equivalent thermal performance per inch. In EV batteries, the challenge is different: a thermal barrier must simultaneously insulate (slow heat transfer between cells), withstand extreme temperatures during a runaway event (>800°C), and remain thin enough to fit within tight battery pack packaging constraints. Aerogel satisfies all three simultaneously. [S3][S10]

Manufacturing process: ASPN uses a sol-gel synthesis process (mixing silica precursors into a wet gel) followed by supercritical drying — a high-pressure, high-temperature CO₂ extraction step that removes liquid from the gel matrix without collapsing the porous structure. This is the critical proprietary step; alternative drying processes produce lower-quality aerogel. Supercritical drying requires specialized pressure vessels and is capital-intensive, which is why the Statesboro plant represented $300M+ in capex. [S2][S3]

IP position: ASPN holds patents on aerogel blanket compositions, manufacturing processes, and specific PyroThin cell-level configurations. Patent coverage gives meaningful near-term protection, but aerogel chemistry is not a black box — the barriers are process know-how, OEM qualification, and production scale, not patents alone. [S2]

6. Business Model Strengths and Vulnerabilities

Strengths:

• Genuine performance differentiation — aerogel's physical properties are not marketing; they represent measurable thermal conductivity advantages over alternatives [S10]
• OEM qualification moat in TB: 3–5 year requalification timelines protect incumbent position at GM even if relationships stress [S3]
• EI segment provides stable cash flow and fixed-cost coverage independent of TB volatility [S2]
• First-mover advantage in commercialized Western EV thermal barrier aerogel at automotive scale [S8]

Vulnerabilities:

• Single-customer concentration in TB (GM ~95%+) creates existential demand risk — one OEM's product decisions drive the majority of ASPN's revenue and all of its growth [S2]
• Manufacturing overcapacity post-Statesboro write-off: East Providence alone may not support $300M+ TB revenues if GM recovers, requiring another capex cycle [S2]
• Capital intensity: aerogel manufacturing requires continuous reinvestment; the business is not asset-light and free cash flow is episodic [S2][S3]
• EV demand uncertainty: the entire TB thesis depends on OEM EV production recovering and ASPN retaining share as battery chemistries (including LFP, which has lower thermal runaway risk) evolve [S9]
• Chinese aerogel producers (notably Nano Tech) are scaling rapidly with lower cost structures, though they lack Western OEM qualification for automotive applications as of 2025 [S10]

7. Key Financial Metrics at a Glance

Revenue per segment illustrates the TB ramp-and-crash dynamic. Q1 2026 at $37.9M total implies a $150M annualized run rate — a catastrophic decline from FY2024's $453M peak — and market cap at $482M prices in either recovery or acquisition premium. [S1][S2][S5]

8. Source Index

source: coverage-next-full ticker: ASPN step: 04 title: Financial Quality & Adversarial Research Sweep date: 2026-06-17

Step 04 — Financial Quality & Adversarial Research Sweep

Aspen Aerogels, Inc. (NYSE: ASPN)

1. Executive Summary

Aspen Aerogels presents one of the more complex financial quality cases in small-cap industrials: a genuine product and technology (PyroThin aerogel thermal barriers for EV battery packs) that attracted real customer adoption, followed by an over-leveraged capacity build for a single customer whose volumes collapsed. The FY2025 GAAP income statement is nearly unintelligible without normalization — a $389.6M net loss on $271M of revenue reflects $291.2M in non-cash Statesboro impairment charges plus associated restructuring. Stripped of those one-time items, the normalized picture is painful but survivable: approximately -$65M net loss on revenues that fell 40% year-over-year as GM dramatically curtailed EV production.

Key financial quality concerns: (1) the Statesboro write-off crystallizes ~$300M of value destruction from a "build-for-one-customer" capacity bet that was entirely rational in 2022 but proved catastrophically wrong; (2) the MidCap credit facility was amended twice in 2025, including removal of the EBITDA covenant in December 2025, signaling meaningful lender accommodation; (3) the April 8, 2026 explosion at East Providence — ASPN's sole remaining manufacturing facility — created a force-majeure supply disruption that rendered Q1 2026 revenue ($37.9M) essentially a floor print; (4) CFO Ricardo Rodriguez departed October 2025 after insider selling near the stock's peak. On balance, this is a financially stressed but not fatally broken company: $157M+ cash, net cash position, insurance coverage for the plant disruption, and a meaningful $37.6M GM commercial settlement received in Q1 2026 provide a credible 12–18 month liquidity runway. The financial quality score is 4/10 — below average due to single-customer concentration risk that materialized, aggressive capex that was subsequently written off, management credibility concerns, and ongoing plant disruption risk.

2. Statement Quality Adjustments

FY2025 Normalization

The reported FY2025 financials require substantial adjustments to understand recurring economics [S1]:

The $291.2M impairment charge consists of $286.6M in long-lived asset impairment for the Statesboro facility plus approximately $4.6M in additional losses on assets held for sale [S2]. These are genuine economic losses — the cash was already spent in FY2022–FY2023 capex — but they are non-recurring items that inflate the reported loss by 4.5× and obscure the underlying operating trend.

Restructuring and accelerated depreciation added approximately $9–10M in additional charges. Excluding all Statesboro-related items, normalized operating loss was approximately -$30M to -$35M on $271M revenue — a normalized operating margin of roughly -12%, worsening from FY2024's +12% as GM volumes collapsed.

FY2024: The Peak Year

FY2024 ($453M revenue, 40% gross margin, +$55M operating income) represented ASPN's first-ever year of GAAP operating profitability and remains the reference point for the bull case. Revenue grew 90% year-over-year, driven almost entirely by PyroThin shipments to GM's Ultium platform. The quality of FY2024 earnings is moderate: the gross margin expansion from 32% (FY2023) to 40% was real operating leverage, but the concentration risk was also at its highest point — GM represented approximately 64% of FY2024 revenue [S3].

FY2023: Investment Trough

FY2023 gross margins of 32% (up from 18% in FY2022) reflected genuine mix improvement as PyroThin scaled. The -$16M operating loss was largely capex-cycle related (high D&A from Statesboro construction-in-progress, partly offset by improving gross profits). Revenue recognition is straightforward — physical shipments of manufactured product — reducing the risk of aggressive accrual accounting.

3. Cash Flow Quality

OCF vs. Net Income Reconciliation

The divergence between OCF and net income in FY2025 is extreme but explainable [S1]:

The massive FY2025 OCF/net income gap is almost entirely explained by the non-cash $291.2M impairment charge being added back in the cash flow reconciliation — this is accounting mechanics, not a quality concern in isolation. However, the more important signal is that FY2025 OCF was only +$20M despite $410M of non-cash add-backs suggesting a working capital drag of approximately $100M+ as revenues collapsed. This likely reflects inventory build (Statesboro-related materials), receivables normalization timing, and restructuring cash costs.

The TTM OCF of approximately +$36M (including Q1 2026's +$34.1M, boosted materially by the $37.6M GM settlement received in cash) is optically better than the run-rate underlying business. Excluding the one-time GM settlement, Q1 2026 OCF would likely have been close to breakeven or negative, consistent with the -$12.7M Adjusted EBITDA reported for the quarter [S4].

Capex Cycle Analysis

The capex profile tells the story of the strategic bet and its reversal:

• FY2022: -$272M capex — Statesboro Phase 1 construction
• FY2023: -$218M capex — Statesboro completion + East Providence upgrade
• FY2024: -$100M capex — tapering; focus on operationalizing capacity
• FY2025: -$25M capex — hard pivot; Statesboro abandoned
• FY2026 guidance: maintenance-level capex, sub-$20M expected

The cumulative capex of approximately $700M over FY2021–FY2025 against cumulative OCF of roughly -$53M implies ASPN consumed approximately $750M+ in total capital over this period. The equity raises and debt that funded this are the primary source of the dilution and leverage discussed in sections 5 and 4 respectively.

Working Capital Dynamics

As revenue collapsed from $453M (FY2024) to $271M (FY2025), one would expect accounts receivable to have declined proportionately. The absence of a large receivables release in FY2025 OCF (it was only +$20M despite $291M+ in non-cash items) suggests either (a) inventory built up as Statesboro wound down, (b) some stretching of collections, or (c) timing of cash receipts across the year-end. The $37.6M GM commercial settlement received in Q1 2026 partially clarifies this picture — it was a retrospective negotiation on contract terms, and its receipt in March 2026 boosted Q1 2026 OCF to +$34.1M [S4]. The underlying Q1 2026 business without this settlement was cash-consuming.

4. Balance Sheet Analysis

Asset Quality

Post-Statesboro write-off, the balance sheet has been substantially cleansed of inflated PP&E [S1]:

• FY2025 total assets: $407M (down from ~$895M pre-impairment)
• Cash & equivalents: $156.9M (FY2025 year-end); rose to $173.9M by Q1 2026 end
• PP&E (net): ~$120–130M — primarily the East Providence facility
• Goodwill/intangibles: minimal — ASPN is a single-site manufacturer
• Inventory: moderate — aerogel rolls and thermal barrier components

The primary asset quality risk now is the East Providence facility itself. The April 8, 2026 explosion rendered ASPN's sole production facility offline at a time when the company is already in a fragile revenue recovery. Insurance claims have been filed (property damage and business interruption) and the company expects a staged restart beginning May 2026 [S5]. A prolonged outage beyond 60–90 days would materially strain the balance sheet despite the cash cushion.

Debt Structure and Covenant Risk

MidCap Financial credit facility (as amended December 2025) [S6]:

• Term loan balance: $86.0M (Q1 2026)
• Revolving credit: $7.1M drawn; additional availability provides liquidity buffer
• EBITDA covenant: removed entirely in December 2025 amendment
• Minimum liquidity covenant: raised to 100% of outstanding term loan principal (~$86M)
• Compliance as of March 31, 2026: confirmed

The removal of the EBITDA covenant is the most significant red flag on the balance sheet. Lenders do not remove financial maintenance covenants for healthy borrowers — they do it to avoid triggering a technical default when they believe a company is in genuine but temporary distress. The fact that MidCap accommodated two amendments in 2025 (May and December) rather than accelerating the debt suggests they view ASPN as a recoverable credit, but the accommodation itself confirms the company was covenant-stressed throughout FY2025. With $173.9M cash vs. $93.1M total debt (term + revolver) as of Q1 2026 end, net cash position is approximately +$80M — meaning the debt is manageable if the business stabilizes, but a further revenue deterioration or prolonged plant outage would erode this cushion quickly.

Net debt-to-normalized EBITDA is not calculable in a meaningful way given negative EBITDA on a trailing basis. On a forward basis, if ASPN achieves its H2 2026 EBITDA breakeven target at $50M/quarter revenue, leverage would be approaching zero on an annualized basis.

5. SBC & Dilution Analysis

Stock-based compensation at ASPN has been persistently elevated relative to company size [S3]:

SBC as a percentage of revenue has improved significantly as ASPN scaled revenue and then cut compensation costs in the restructuring. The 2025 restructuring appears to have meaningfully reduced the SBC burden, with H2 2025 guidance of approximately $5M/half ($10M annualized) — down from peak levels. This is a positive trend.

Dilution: Basic shares outstanding grew from approximately 50M (FY2020) to 82.9M (FY2025) — a 66% increase over five years, implying roughly 10–11% annualized dilution from equity issuances and SBC exercises [S7]. The majority of dilution came from capital raises in FY2021–FY2022 to fund Statesboro construction, not ongoing SBC. However, the equity raises at prices far above current levels (~$30–$50/share range during the buildout vs. current single-digit prices) means that dilution destroyed substantial per-share value.

The insider selling incident — former CFO Ricardo Rodriguez sold approximately $978K of stock at roughly $30/share in August 2024 shortly before the stock collapsed to single digits — is discussed in Section 6 below.

6. Adversarial Research Sweep

6a. Short Seller Reports and Bearish Theses

No formal short seller report (Hindenburg, Citron, Muddy Waters style) was identified for ASPN in searches through June 2026 [S8]. The absence of a formal short report is notable — ASPN's concentrated customer exposure, aggressive capex, and subsequent impairment would typically attract short-seller attention. The most likely explanation is that the stock's ~85% decline from peak ($30+ in 2024 to ~$3–5 in early 2026) occurred through fundamental deterioration rather than an externally exposed fraud.

The bearish consensus among sell-side analysts centers on: (1) GM EV production resets to approximately 176,000 Ultium-platform vehicles in 2026 vs. prior peak expectations, (2) solid-state battery technology as a long-term demand threat (if successful, eliminates the need for thermal barrier insulation), and (3) customer concentration that structurally limits pricing power. Multiple analysts have cut price targets to the $3–6 range. Short interest as tracked by Fintel has been meaningful but not extraordinary, consistent with a value-deterioration short thesis rather than a fraud thesis [S8].

6b. Litigation and Regulatory Issues

Material litigation as of the most recent filings is limited [S1][S9]:

• AMA Patent Dispute (Italy): Aspen settled its patent infringement action against AMA S.p.A. and AMA Composites S.r.l. in January 2025. AMA had allegedly sold infringing aerogel insulation in Europe. Settlement terms were not disclosed publicly but the case is closed.
• GM Commercial Settlement ($37.6M): Received in Q1 2026. This is the most significant financial litigation-adjacent event — it suggests a disputed contract claim (likely related to volume shortfalls vs. contractual commitments) that Aspen pursued successfully. The settlement is recognized over approximately two years (deferred revenue treatment), reducing the cash-to-revenue recognition mismatch risk.
• East Providence Regulatory/Safety Investigations: The April 8, 2026 explosion is subject to investigation by local, state, and federal agencies (OSHA at minimum). No OSHA citations or enforcement actions have been publicly reported as of June 2026. Eleven employees required medical evaluation; all were reportedly released. Potential liability exposure from worker injuries or property damage beyond insurance limits is a tail risk [S5].
• No SEC investigation or restatement identified: SEC EDGAR searches show no comment letters with material accounting disputes and no restatements in the public record.

6c. Accounting Red Flags

Several items warrant scrutiny but do not rise to the level of fraud indicators:

1. Statesboro Impairment Timing: The $291.2M impairment was recorded in Q1 2025. Questions arise about whether the write-down should have come sooner — by mid-2024, GM's EV production revisions were becoming public. Had Aspen tested the long-lived assets more aggressively during FY2024, an impairment could arguably have been triggered then. However, impairment testing requires demonstrating that carrying value exceeds fair value using a probability-weighted future cash flow model, and the asset technically had ongoing utility as long as a customer relationship existed. The timing does not appear to constitute an accounting irregularity, though it was at the outer edge of defensible.

2. Revenue Recognition: PyroThin revenue is recognized on physical shipment (point-in-time), reducing accrual gaming risk. The $37.6M GM settlement's two-year deferred recognition is appropriate under ASC 606 (it represents a contract modification with future performance obligations). No evidence of pull-forward revenue recognition was identified.

3. Capitalized Costs: Statesboro construction costs were appropriately capitalized as PP&E under GAAP. The retrospective question is whether the investment decision was sound — it was not — but the accounting treatment was correct.

4. D&A and PP&E Life Assumptions: Post-Statesboro, D&A will decline sharply as the written-off assets leave the depreciation schedule. This will mechanically improve reported earnings in FY2026 regardless of operational performance. Investors should be aware that this "accounting tailwind" is an artifact of the write-off, not operational improvement.

6d. Management Credibility Issues

Two events raise management credibility concerns:

CFO Departure (October 2025): Ricardo Rodriguez joined ASPN in November 2021 as Chief Strategy Officer and was appointed CFO in April 2022 — during the peak of the Statesboro buildout. He departed in October 2025, concurrent with the Q3 2025 earnings release, replaced by an internal successor, Grant Thoele. The departure timing — after the impairment was booked but while the company is in restructuring — is consistent with a board-initiated change rather than voluntary resignation. The internal succession (rather than an external hire) somewhat reduces concern about a "clean house" scenario. Nonetheless, Rodriguez oversaw the financial planning and capital structure decisions that accompanied the aggressive Statesboro buildout, and his departure at this juncture is not confidence-inspiring [S9].

Insider Selling at Peak: Former CFO Rodriguez sold approximately $978K of ASPN stock at approximately $30/share in August 2024. The stock subsequently declined approximately 85% to the $4–5 range by early 2026. While $978K is not a massive sum relative to total company market cap, the timing — selling near the stock's all-time high, roughly 6–8 months before the company would disclose Statesboro impairment — raises questions. Sales under a pre-arranged 10b5-1 plan would reduce (though not eliminate) the inference of information asymmetry. SEC Form 4 filings show the transaction but available search results do not confirm whether a 10b5-1 plan was in place [S10]. This remains an open adversarial question.

6e. Customer Concentration Risk — What Actually Happened with GM

The GM concentration story is the central financial quality failure at ASPN:

• Peak concentration (FY2024): GM represented approximately 64% of total revenue (~$290M of $453M), almost entirely through PyroThin thermal barrier shipments for Ultium-platform vehicles (Chevrolet Silverado EV, Blazer EV, Equinox EV, GMC Sierra EV, Hummer EV)
• The collapse: GM significantly revised its EV production targets in late 2024 and into 2025 as consumer EV adoption lagged expectations. GM's Ultium platform vehicles saw slower sales than anticipated, and GM deferred several planned EV model introductions. For ASPN, this meant PyroThin revenue fell from $306.8M (FY2024) to approximately $168.9M (FY2025) — a 45% decline in one product line from one customer [S3]
• Statesboro was built to serve GM: The $490M+ in total Statesboro-related capex was premised on GM requiring a second aerogel plant to meet Ultium production targets. When GM's EV production plans reset, the asset had no alternative use case at scale. The $291.2M impairment follows directly
• Q1 2026 GM revenue ($16.3M thermal barrier): Annualizes to roughly $65M — approximately 22% of FY2024 peak levels. GM's 2026 EV production forecast of ~176,000 Ultium vehicles (up 25% from 2025's depressed levels) suggests some recovery, but the concentration risk remains
• European pivot: ASPN has announced wins with unspecified European OEMs for PyroThin supply, which management cites as the primary diversification strategy. No revenue impact has yet been disclosed; the geographic pivot is a medium-term story at best

6f. SEC Comment Letters and Restatements

No evidence of SEC comment letter exchanges raising material accounting concerns was identified in searches through June 2026. No financial restatements appear in the public record. The FY2025 10-K was filed on the standard schedule without extension, and there is a subsequent 10-K/A amendment noted in SEC EDGAR [S1], though the nature of the amendment (likely immaterial technical corrections) is not detailed in available sources.

7. Financial Quality Score

Score: 4 / 10

Overall: 4/10. Below-average financial quality. The company operates a real business with genuine product-market fit, but has demonstrated poor capital allocation discipline (Statesboro), dangerous single-customer concentration, and questionable management actions around the stock's peak. The balance sheet is stabilizing post-impairment, and the absence of accounting fraud or restatements provides a floor. The score would improve toward 6/10 if: (a) East Providence restarts without further incident, (b) European OEM revenue diversifies the customer base, and (c) management demonstrates EBITDA breakeven by H2 2026 as guided.

8. Source Index

• [S1] Aspen Aerogels FY2025 10-K (Annual Report) — SEC EDGAR, ASPN (CIK 0001145986)
• [S2] Aspen Aerogels Q1 2025 Earnings Release (8-K) — SEC EDGAR; Statesboro impairment $286.6M + $4.6M loss on assets held for sale
• [S3] Aspen Aerogels FY2024 10-K — GM customer concentration (64% of revenue), PyroThin revenue breakdown
• [S4] Aspen Aerogels Q1 2026 10-Q — SEC EDGAR (filed May 8, 2026); cash $173.9M, OCF +$34.1M, GM settlement $37.6M deferred, MidCap covenant compliance
• [S5] Aspen Aerogels East Providence Facility Update — GlobeNewswire, April 21, 2026; staged restart May 2026; insurance claims initiated
• [S6] Aspen Aerogels MidCap Credit Facility Amendment Announcement — GlobeNewswire, December 17, 2025; EBITDA covenant removed, liquidity covenant revised
• [S7] Aspen Aerogels Shares Outstanding Historical Data — MacroTrends ASPN; ~50M to ~82.9M shares FY2020–FY2025
• [S8] Fintel.io ASPN Short Interest Data; web searches for Hindenburg/Citron/Muddy Waters ASPN reports — no formal short report identified as of June 2026
• [S9] Aspen Aerogels Q2 2025 Earnings Release (8-K) — CFO transition announcement; Rodriguez departure October 2025, Thoele successor
• [S10] SEC Form 4 Filings — Ricardo Rodriguez insider sales August 2024; GuruFocus insider trading records; 10b5-1 plan status unconfirmed in available sources
• [S11] Aspen Aerogels AMA Patent Settlement Press Release — PR Newswire, January 2025; Italian patent dispute resolved

Step 04 of 20 | Coverage-Next-Full | No earnings transcripts — sources: 10-K/10-Q/8-K MD&A, press releases, SEC filings, web search